热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　野村证券发布研报称，给予药明生物（02269）“买入”评级，将其目标价由19.3港元上调58.5%至30.59港元。因管理层在JPM医疗保健会议期间更新了2024财年签署的综合项目数量创历史新高（151个，而该行之前预测为91个），野村将药明生物的2024及2025年度收入预测上调7%及9.8%，2024及2025年度盈利预测上调8.3%/11.4%。

　　该行对药明生物2024及2025年度的收入预测比彭博共识高出2.8%/1.8%，而该行的盈利预测比彭博共识低7.9%及8.9%，主要由于野村对利用率的毛利率预测更为审慎（2024及2025年度同比下降1.1个百分点/同比增加0.3个百分点）。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.